$17.83
Value $3.0B
ACAD and JNJ stock compared: price, dividend, valuation and results, from SEC filings.
$17.83
Value $3.0B
$272.70
Value $657B
ACADIA Pharmaceuticals (ACAD) has a market value of $3.0B and Johnson & Johnson (JNJ) $657B. Over the last year, with dividends, ACAD moved -25.7% and JNJ +39.7%. Dividend yield: ACAD none, JNJ 1.94%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
ACAD$3.0B
JNJ$657B
JNJ is 216 times ACAD
Revenue, 12 months
ACAD$1.2B
JNJ$99.3B
JNJ is 83 times ACAD
Net income, 12 months
ACAD$362M
JNJ$16.1B
JNJ is 44 times ACAD
Operating margin
ACAD10.2%
JNJ–
ROIC
ACAD7.9%
JNJ12.4%
4.5 points apart
P/E
ACAD–
JNJ40.8
Dividend yield
ACAD0.0%
JNJ1.9%
1.9 points apart
5-year return
ACAD-8.5%
JNJ+92.0%
100.5 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
ACAD-8.5%
JNJ+92.0%
| Period | ACADWith dividends | JNJWith dividends |
|---|---|---|
| 1 year since November 17, 2025 | -25.7%Price -25.7% | +39.7%Price +36.6% |
| 3 years since November 17, 2023 | -21.9%-7.9% a yearPrice -21.9% | +98.2%+25.6% a yearPrice +82.1% |
| 5 years since November 17, 2021 | -8.5%-1.8% a yearPrice -8.5% | +92.0%+13.9% a yearPrice +67.0% |
| 10 years since November 18, 2016 | -39.6%-4.9% a yearPrice -39.6% | +208.0%+11.9% a yearPrice +136.4% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
ACADACADIA PharmaceuticalsJNJJohnson & Johnson
| Price | $17.83 | $272.70 |
|---|---|---|
| Market value | $3.0B | $657B |
| Enterprise value (EV) | $2.1B | $685B |
| P/E | – | 40.8 |
| P/E, 5-year median | – | 21.9 |
| P/B | 2.2 | 8.1 |
| EV/EBIT | 16.9 | 38.6 |
| Free cash flow yield | 2.7% | 3.1% |
| Revenue, 12 months | $1.2B | $99.3B |
|---|---|---|
| Net income, 12 months | $362M | $16.1B |
| Free cash flow, 12 months | $82M | $20.6B |
| Earnings per share, 12 months | $2.12 | $6.59 |
| Revenue growth, year on year | 11.9% | 6.1% |
| Revenue growth a year, past | +19.4%over 5 years | +2.7%over 5 years |
| EPS growth a year, past | – | +14.9%over 5 years |
| Gross margin | 90.5% | 67.6% |
|---|---|---|
| Operating margin | 10.2% | – |
| Net margin | 30.1% | 16.2% |
| ROIC | 7.9% | 12.4% |
| ROE | 29.8% | 19.7% |
| Cash | $976M | $17.2B |
|---|---|---|
| Total debt | $72M | $44.7B |
| Net debt / EBITDA | -7.9 | 1.1 |
| Interest cover | – | 18.0× |
| Dividend yield | – | 1.9% |
|---|---|---|
| Dividend per share, 12 months | – | $5.28 |
| Dividend growth a year, past | – | +5.3%over 5 years |
| Buyback yield | – | 0.9% |
| Shareholder yield | – | 2.9% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Johnson & Johnson ($657B) is about 216.2 times ACADIA Pharmaceuticals ($3.0B), at today's prices.
Since November 18, 2016, ACAD's price moved -39.6% and JNJ's +136.4%. With dividends: ACAD -39.6% (-4.9% a year), JNJ +208.0% (+11.9% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for ACADIA Pharmaceuticals and 1.94% for Johnson & Johnson. Over the last twelve months they paid – and $5.28 per share.
Over the last twelve months, the net margin was 30.1% for ACADIA Pharmaceuticals and 16.2% for Johnson & Johnson, and the operating margin 10.2% and –. Revenue was $1.2B and $99.3B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.